杏林製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/05/17 | 1,710 | 1,716 | 1,703 | 1,712 | +2 | +0.1% | 107,100 |
| 2024/05/16 | 1,725 | 1,725 | 1,705 | 1,710 | -18 | -1% | 86,100 |
| 2024/05/15 | 1,735 | 1,765 | 1,724 | 1,728 | +8 | +0.5% | 127,300 |
| 2024/05/14 | 1,750 | 1,754 | 1,720 | 1,720 | -33 | -1.9% | 131,400 |
| 2024/05/13 | 1,795 | 1,795 | 1,733 | 1,753 | -76 | -4.2% | 138,600 |
| 2024/05/10 | 1,831 | 1,832 | 1,820 | 1,829 | +7 | +0.4% | 34,500 |
| 2024/05/09 | 1,819 | 1,834 | 1,809 | 1,822 | +22 | +1.2% | 31,800 |
| 2024/05/08 | 1,837 | 1,837 | 1,800 | 1,800 | -35 | -1.9% | 34,200 |
| 2024/05/07 | 1,839 | 1,840 | 1,829 | 1,835 | -4 | -0.2% | 30,500 |
| 2024/05/02 | 1,836 | 1,842 | 1,829 | 1,839 | +1 | +0.1% | 22,400 |
| 2024/05/01 | 1,826 | 1,843 | 1,821 | 1,838 | -1 | -0.1% | 28,900 |
| 2024/04/30 | 1,828 | 1,839 | 1,816 | 1,839 | +11 | +0.6% | 52,600 |
| 2024/04/26 | 1,810 | 1,828 | 1,801 | 1,828 | +18 | +1% | 84,900 |
| 2024/04/25 | 1,825 | 1,825 | 1,805 | 1,810 | +3 | +0.2% | 55,500 |
| 2024/04/24 | 1,812 | 1,825 | 1,801 | 1,807 | -5 | -0.3% | 73,700 |
| 2024/04/23 | 1,808 | 1,813 | 1,797 | 1,812 | +7 | +0.4% | 54,600 |
| 2024/04/22 | 1,791 | 1,810 | 1,791 | 1,805 | +28 | +1.6% | 56,900 |
| 2024/04/19 | 1,793 | 1,795 | 1,764 | 1,777 | -17 | -0.9% | 71,900 |
| 2024/04/18 | 1,790 | 1,801 | 1,785 | 1,794 | +7 | +0.4% | 37,900 |
| 2024/04/17 | 1,795 | 1,798 | 1,778 | 1,787 | -16 | -0.9% | 48,800 |
| 2024/04/16 | 1,812 | 1,817 | 1,795 | 1,803 | -25 | -1.4% | 45,700 |
| 2024/04/15 | 1,812 | 1,830 | 1,807 | 1,828 | +2 | +0.1% | 50,500 |
| 2024/04/12 | 1,830 | 1,831 | 1,818 | 1,826 | +4 | +0.2% | 33,300 |
| 2024/04/11 | 1,820 | 1,828 | 1,811 | 1,822 | -11 | -0.6% | 39,700 |
| 2024/04/10 | 1,820 | 1,833 | 1,820 | 1,833 | +11 | +0.6% | 41,800 |
| 2024/04/09 | 1,820 | 1,826 | 1,803 | 1,822 | +2 | +0.1% | 40,300 |
| 2024/04/08 | 1,815 | 1,825 | 1,800 | 1,820 | +11 | +0.6% | 48,500 |
| 2024/04/05 | 1,795 | 1,810 | 1,787 | 1,809 | +14 | +0.8% | 32,700 |
| 2024/04/04 | 1,803 | 1,807 | 1,789 | 1,795 | -10 | -0.6% | 57,000 |
| 2024/04/03 | 1,785 | 1,809 | 1,783 | 1,805 | +14 | +0.8% | 55,000 |
| 2024/04/02 | 1,791 | 1,803 | 1,779 | 1,791 | -13 | -0.7% | 79,000 |
| 2024/04/01 | 1,802 | 1,815 | 1,793 | 1,804 | -8 | -0.4% | 52,600 |
| 2024/03/29 | 1,815 | 1,832 | 1,806 | 1,812 | -5 | -0.3% | 56,400 |
| 2024/03/28 | 1,808 | 1,836 | 1,808 | 1,817 | -40 | -2.2% | 82,500 |
| 2024/03/27 | 1,853 | 1,880 | 1,851 | 1,857 | +21 | +1.1% | 173,600 |
| 2024/03/26 | 1,825 | 1,839 | 1,809 | 1,836 | +2 | +0.1% | 86,900 |
| 2024/03/25 | 1,825 | 1,855 | 1,820 | 1,834 | +19 | +1% | 165,200 |
| 2024/03/22 | 1,800 | 1,823 | 1,796 | 1,815 | +19 | +1.1% | 97,300 |
| 2024/03/21 | 1,800 | 1,812 | 1,795 | 1,796 | +4 | +0.2% | 93,300 |
| 2024/03/19 | 1,785 | 1,792 | 1,779 | 1,792 | +8 | +0.4% | 43,000 |
| 2024/03/18 | 1,799 | 1,799 | 1,780 | 1,784 | -2 | -0.1% | 43,300 |
| 2024/03/15 | 1,784 | 1,797 | 1,776 | 1,786 | +2 | +0.1% | 81,300 |
| 2024/03/14 | 1,785 | 1,785 | 1,768 | 1,784 | +8 | +0.5% | 37,800 |
| 2024/03/13 | 1,785 | 1,793 | 1,768 | 1,776 | -9 | -0.5% | 49,200 |
| 2024/03/12 | 1,788 | 1,788 | 1,761 | 1,785 | -3 | -0.2% | 49,000 |
| 2024/03/11 | 1,803 | 1,803 | 1,776 | 1,788 | -15 | -0.8% | 51,800 |
| 2024/03/08 | 1,781 | 1,811 | 1,781 | 1,803 | +17 | +1% | 129,200 |
| 2024/03/07 | 1,770 | 1,786 | 1,766 | 1,786 | +24 | +1.4% | 65,000 |
| 2024/03/06 | 1,763 | 1,780 | 1,762 | 1,762 | -1 | -0.1% | 59,700 |
| 2024/03/05 | 1,771 | 1,774 | 1,746 | 1,763 | -13 | -0.7% | 44,500 |
1～
50
件表示中 / 3457件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 杏林製薬 | 171,200円 | +3.2% | +4.5% | 3.04% | 19.67倍 | 0.75倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| 持田薬 | 305,500円 | +3.0% | +27.5% | 2.62% | 19.34倍 | 0.85倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
| 鳥居薬 | 389,500円 | +7.3% | +16.8% | 3.08% | 23.30倍 | 0.91倍 |
|
ＪＴ傘下。自社製品の腎・透析、アレルゲン等の開発強化。柱の抗ＨＩＶ薬の販売権喪失が直撃 |
| ジーエヌアイ | 217,800円 | +52.1% | +23.3% | 0.00% | 15.39倍 | 3.21倍 |
|
創薬ベンチャー。米国で人工骨も。中国の特発性肺線維症薬で高シェア、米中に研究開発機能 |
| ゼリア新薬 | 200,900円 | +9.6% | +17.5% | 2.29% | 11.35倍 | 1.11倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
市場注目の銘柄
チャート関連のコラム
